SPY761.15+1.50%QQQ693.63+2.80%BTC/USD74,168.00+0.64%DIA524.10+0.45%GLD365.24−1.12%TLT80.86−0.02%

Premium Services

Premium Services

AstraZeneca PLC

AZNNYSE

Trade with Public

Trade with Public

$184.78

-1.98-1.06%

Last update: Nov 11, 2:06 PM

Overview News Charts Earnings Forecast EventsPrice TargetsFinancials Sentiment Ownership Dividends Compare Options Stock Report

Connect With Us

About Benzinga

Market Resources

Advanced Stock Screener Tools
Options Trading Chain Analysis
Comprehensive Earnings Calendar
Dividend Investor Calendar and Alerts
Economic Calendar and Market Events
IPO Calendar and New Listings
Market Outlook and Analysis
Wall Street Analyst Ratings and Targets

Trading Tools & Education

Ring the Bell

© 2026 Benzinga | All Rights Reserved

AstraZeneca (AZN) Stock Price Target 2026 & Analyst Forecast - Benzinga

AstraZeneca (AZN) Stock Price Target 2026

The average analyst price target for AstraZeneca is $107, 42.1% below the current price. Of 10 analysts, 9 rate it Buy and 1 Hold. Targets range from $82 to $198. The latest change came on Aug 24, 2026, when CICC initiated coverage of AstraZeneca with an Outperform rating and a $198 price target.

The Average Analyst Price Target for AstraZeneca is $107.

Price Target Range — 4 Quarters

Analyst Consensus — 10 Analysts

9Buy

1Hold

Consensus RatingBuy# Analysts10Avg. Consensus PT$107Upside to Avg. PT-42.1%

Rating Trend — Last 9 Months

Latest Upgrades and Downgrades for AstraZeneca Stock

See all ratings →

Date	Firm	Analyst	Action	Rating Change	Price Target
Aug 24, 2026	CICC	Yuan Guo	Initiate	Outperform	$198
Oct 27, 2025	Jefferies	Michael Leuchten	Assumes	Hold→Buy	—
Feb 13, 2025	UBS	Matthew Weston	Upgrade	Neutral→Buy	—
Nov 20, 2024	UBS	Matthew Weston	Upgrade	Sell→Neutral	—
Sep 11, 2024	Erste Group	Hans Engel	Upgrade	Hold→Buy	—
Aug 12, 2024	TD Cowen	Steve Scala	PT Raise	Buy	$90→$95
May 30, 2024	Argus Research	Jasper Hellweg	PT Raise	Buy	$80→$85
May 30, 2024	Goldman Sachs	Rajan Sharma	Initiate	Buy	$97
Apr 26, 2024	BMO Capital	Etzer Darout	PT Raise	Outperform	$80→$82
Apr 16, 2024	Deutsche Bank	Emmanuel Papada	Upgrade	Sell→Hold	—
Feb 12, 2024	BMO Capital	Etzer Darout	PT Cut	Outperform	$82→$80
Feb 8, 2024	Deutsche Bank	Emmanuel Papadakis	Downgrade	Buy→Hold	—
Jan 23, 2024	Morgan Stanley	Mark Purcell	Initiate	Overweight	$85
Jan 3, 2024	Jefferies	Peter Welford	Downgrade	Buy→Hold	—

Analyst Ratings News

AstraZeneca Analyst Raises Price Target On Q3 Results, Shift In Avanzar Timing

AstraZeneca posts strong Q3; RBC raises target, citing reduced AVANZAR uncertainty and promising pipeline catalysts.

Priya Nigam

Eli Lilly Gets Full FDA Approval for Inluriyo in ESR1-Mutated Breast Cancer

The FDA fully approves Eli Lilly's Inluriyo and Verzenio combination for advanced breast cancer, doubling progression-free survival.

Vandana Singh

This $3 Biotech Could Be Worth $11.45, Analyst Says

William Blair initiates Perspective Therapeutics (NYSE: CATX) at Outperform, citing its strong radiopharmaceutical platform.

Vandana Singh

This Small Biotech’s Cancer Drug Could Reach $1.3 Billion In Peak Sales

William Blair initiates Zentalis (ZNTL) at Outperform, citing a $1.3B peak sales potential for lead cancer drug azenosertib.

Vandana Singh

PRO
CNBC Halftime Report Final Trades: AstraZeneca, Leidos Holdings, Expeditors International of Washington, U.S. 10 Year Treasury

Benzinga Newsdesk

BioMarin Seeks to Strengthen Market Position in Rare Bone Disease Treatment

BioMarin Pharmaceutical agrees to acquire Alesta Therapeutics for $275 million upfront, securing ALE1 for rare bone disease treatment.

Vandana Singh